Skip to main content
Clinical Trials/CTRI/2018/03/012268
CTRI/2018/03/012268
Recruiting
未知

Genzyme rare disease registries (Fabry Disease Registry Protocol)

Sanofi Synthelabo India Private Limited0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- Fabry DiseaseHealth Condition 2: E752- Other sphingolipidosis
Sponsor
Sanofi Synthelabo India Private Limited
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Sanofi Synthelabo India Private Limited

Eligibility Criteria

Inclusion Criteria

  • 1\. all age group from new born to old age allowed.
  • 2\. All patients with a confirmed diagnosis of Fabry disease who are willing and able to provide written informed consent and any additional authorization documents required by local law to send health information to the Registry are eligible for inclusion, regardless of whether they are receiving disease therapy including enzyme replacement therapy (ERT) (such as agalsidase beta) and irrespective of the commercial product with which they are being treated.
  • 3\. A confirmed diagnosis is defined as a documented deficiency in plasma or leukocyte αGAL enzyme activity and/or mutation(s) in the gene coding for αGA

Exclusion Criteria

  • No exclusion criteria, its a disease registry

Outcomes

Primary Outcomes

Not specified

Similar Trials